SCHEMBL10124936

SCHEMBL10124936

CCCOc1ccccc1-c1ccnc2[nH]ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 2/20 0.52
IKBKB O14920 1/20 0.52
CHUK O15111 1/20 0.52
DAPK3 O43293 1/20 0.52
JAK2 O60674 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
PAK4 O96013 1/20 0.52
CSF1R P07333 1/20 0.52
RET P07949 1/20 0.52
IGF1R P08069 1/20 0.52
FGFR1 P11362 1/20 0.52
PRKACA P17612 1/20 0.52
FLT1 P17948 1/20 0.52
LTK P29376 1/20 0.52
GRK5 P34947 1/20 0.52
KDR P35968 1/20 0.52
MAP2K2 P36507 1/20 0.52
MAPK8 P45983 1/20 0.52
CSNK1A1 P48729 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10125146 0.93 AURKB (0.51) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL859080 0.89 AURKB (0.55) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL858602 0.83 BRD4 (0.62) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL10125078 0.81 AURKB (0.56) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL2988049 0.81 NUDT1 (0.52) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL30461709 0.81 NUDT1 (0.52) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL12127803 0.80 AURKB (0.51) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL10125438 0.80 AURKB (0.54) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL10125431 0.78 AURKB (0.59) AURKBIKBKBCHUKDAPK3JAK2
SCHEMBL10125117 0.77 NUDT1 (0.58) AURKBIKBKBCHUKDAPK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921376-B2 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-30 US disclosed
US-8921376-B2 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-30 US disclosed
EP-1881983-B1 PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMA (US) 2012-01-11 EP disclosed
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-06-14 US disclosed
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase JAK2, JAK1, JAK3 AURKB 478/4885IKBKB 779/4885CHUK 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.